AU2020396557A1 - Protein-loaded PLGA nanospheres - Google Patents

Protein-loaded PLGA nanospheres Download PDF

Info

Publication number
AU2020396557A1
AU2020396557A1 AU2020396557A AU2020396557A AU2020396557A1 AU 2020396557 A1 AU2020396557 A1 AU 2020396557A1 AU 2020396557 A AU2020396557 A AU 2020396557A AU 2020396557 A AU2020396557 A AU 2020396557A AU 2020396557 A1 AU2020396557 A1 AU 2020396557A1
Authority
AU
Australia
Prior art keywords
protein
emulsion
plga
composition
nanospheres
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2020396557A
Other languages
English (en)
Inventor
Ryan A. LACINSKI
Brock A. LINDSEY
Justin E. MARKEL
Jabeen NOORE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
West Virginia University
Original Assignee
West Virginia University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by West Virginia University filed Critical West Virginia University
Publication of AU2020396557A1 publication Critical patent/AU2020396557A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/208—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5192—Processes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Optics & Photonics (AREA)
  • Nanotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
AU2020396557A 2019-12-05 2020-12-04 Protein-loaded PLGA nanospheres Pending AU2020396557A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962944191P 2019-12-05 2019-12-05
US62/944,191 2019-12-05
PCT/US2020/063314 WO2021113638A1 (en) 2019-12-05 2020-12-04 Protein-loaded plga nanospheres

Publications (1)

Publication Number Publication Date
AU2020396557A1 true AU2020396557A1 (en) 2022-06-23

Family

ID=76221229

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020396557A Pending AU2020396557A1 (en) 2019-12-05 2020-12-04 Protein-loaded PLGA nanospheres

Country Status (11)

Country Link
US (3) US12214046B2 (https=)
EP (1) EP4072536A4 (https=)
JP (1) JP7818514B2 (https=)
KR (1) KR20220143811A (https=)
CN (1) CN115335041A (https=)
AU (1) AU2020396557A1 (https=)
BR (1) BR112022010952A2 (https=)
CA (1) CA3160922A1 (https=)
IL (1) IL293607A (https=)
MX (1) MX2022006824A (https=)
WO (1) WO2021113638A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021113638A1 (en) 2019-12-05 2021-06-10 West Virginia University Protein-loaded plga nanospheres
CN116855571B (zh) * 2023-06-26 2025-03-21 中国农业大学 Plga纳米球病毒示踪剂及其制备方法与应用
KR20250069077A (ko) * 2023-11-10 2025-05-19 아주대학교산학협력단 패티케이션 기술을 적용한 쿠에티아핀-지방산 접합체 나노입자 및 이의 장기 지속형 주사제 용도

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6406719B1 (en) 1998-05-13 2002-06-18 Microbiological Research Authority Encapsulation of bioactive agents
FR2793684B1 (fr) 1999-05-17 2001-08-10 Ethypharm Lab Prod Ethiques Utilisation de microspheres biodegradables liberant un agent anticancereux pour le traitement du glioblastome, procede de preparation de ces microspheres et suspension les contenant
US20040003402A1 (en) 2002-06-27 2004-01-01 Digeo, Inc. Method and apparatus for automatic ticker generation based on implicit or explicit profiling
US6974862B2 (en) 2003-06-20 2005-12-13 Kensey Nash Corporation High density fibrous polymers suitable for implant
US20070026005A1 (en) * 2003-09-09 2007-02-01 Sung Young C Vaccine composition comprising il-12 adjuvant encapsulated in controlled-release microsphere
KR100622996B1 (ko) * 2005-03-03 2006-09-14 한국과학기술원 약물이 봉입된 비다공성 고분자 미립 담체 및 이의 제조방법
WO2007074604A1 (ja) 2005-12-26 2007-07-05 Ltt Bio-Pharma Co., Ltd. 水溶性非ペプチド性低分子薬物含有ナノ粒子
US10265407B2 (en) 2007-02-15 2019-04-23 Yale University Modular nanodevices for smart adaptable vaccines
EP2251006B1 (en) 2008-02-22 2017-07-19 Toray Industries, Inc. Microparticles and pharmaceutical compositions thereof
US9972047B1 (en) 2008-04-18 2018-05-15 Capital One Services, Llc Systems and methods for performing a purchase transaction using rewards points
US20090281888A1 (en) 2008-05-09 2009-11-12 Li-Cheng Richard Zai Method And Apparatus For Establishing Time-Based Loyalty Relationship
EA020954B1 (ru) 2008-06-16 2015-03-31 Бинд Терапьютикс, Инк. Загруженные лекарственным средством полимерные наночастицы, фармацевтическая композиция и способ лечения рака
RU2011126338A (ru) * 2008-11-28 2013-01-10 Эбботт Лэборетриз Стабильные композиции антител и способы их стабилизации
WO2011063177A1 (en) 2009-11-20 2011-05-26 Mobisave Corporation System and method of electronically verifying required proof-of-performance to secure promotional rewards
WO2011119262A1 (en) 2010-03-26 2011-09-29 Cerulean Pharma Inc. Methods and systems for generating nanoparticles
US9782342B2 (en) * 2010-10-11 2017-10-10 Wichita State University Composite magnetic nanoparticle drug delivery system
BR112014006596A2 (pt) * 2011-09-21 2017-03-28 Yissum Res Dev Co nanopartícula que encapsula uma pluralidade de nanocarreadores, composição, uso de uma nanopartícula, kit, sistema de entrega, processo para obter uma nanopartícula, e, processo de nanoaspersão para obter as nanopartículas
US9562015B2 (en) * 2011-11-17 2017-02-07 The Regents Of The University Of Colorado, A Body Methods and compositions for enhanced drug delivery to the eye and extended delivery formulations
CA2869748C (en) * 2012-04-12 2017-10-24 Yale University Vehicles for controlled delivery of different pharmaceutical agents
WO2013166487A1 (en) 2012-05-04 2013-11-07 Yale University Highly penetrative nanocarriers for treatment of cns disease
US9724304B2 (en) 2012-06-14 2017-08-08 Temple University—Of the Commonwealth System of Higher Education Nanospheres for therapeutic agent delivery
US9308172B2 (en) 2012-10-26 2016-04-12 Board Of Trustees Of Michigan State University Device and method for encapsulation of hydrophilic materials
CA2929277C (en) * 2013-11-01 2018-01-16 Yale University Delivery vehicles comprising il-2 and losartan
WO2016061201A1 (en) * 2014-10-14 2016-04-21 The Brigham And Women's Hospital, Inc. Nanoparticles and methods of use
CN104622795B (zh) * 2015-01-28 2017-12-08 杭州市萧山区中医院 一种多细胞因子序贯缓释微球‑水凝胶复合系统及其制备方法
CN108064176A (zh) 2015-04-22 2018-05-22 库瑞瓦格股份公司 用于治疗肿瘤疾病的含有rna的组合物
US20170056327A1 (en) * 2015-08-25 2017-03-02 The Methodist Hospital Micro/nano composite drug delivery formulations and uses thereof
WO2019162951A1 (en) * 2018-02-26 2019-08-29 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd Drug delivery systems
EP3987054A4 (en) 2019-06-18 2023-06-14 Biomeme Incorporated SAMPLE ANALYSIS SYSTEMS
WO2021113638A1 (en) 2019-12-05 2021-06-10 West Virginia University Protein-loaded plga nanospheres

Also Published As

Publication number Publication date
JP2023504282A (ja) 2023-02-02
US20250064949A1 (en) 2025-02-27
CN115335041A (zh) 2022-11-11
US20250073343A1 (en) 2025-03-06
EP4072536A4 (en) 2025-01-15
US20230070180A1 (en) 2023-03-09
IL293607A (en) 2022-08-01
EP4072536A1 (en) 2022-10-19
CA3160922A1 (en) 2021-06-10
WO2021113638A1 (en) 2021-06-10
BR112022010952A2 (pt) 2022-09-06
MX2022006824A (es) 2022-09-19
JP7818514B2 (ja) 2026-02-20
KR20220143811A (ko) 2022-10-25
US12214046B2 (en) 2025-02-04

Similar Documents

Publication Publication Date Title
US20250073343A1 (en) Protein-loaded plga nanospheres
JP6887685B2 (ja) ナノ粒子の細胞表面共役
Xu et al. Prevention of colorectal cancer liver metastasis by exploiting liver immunity via chitosan-TPP/nanoparticles formulated with IL-12
US10987314B2 (en) Antigen-specific, tolerance-inducing microparticles and uses thereof
JP5579586B2 (ja) 腫瘍ワクチン
CN112569207A (zh) 一种载脂蛋白修饰的仿生纳米肿瘤疫苗及其制备方法和用途
JPH09506866A (ja) 医薬として活性のある物質の免疫療法のための放出制御
Jahan et al. Design and immunological evaluation of anti-CD205-tailored PLGA-based nanoparticulate cancer vaccine
Wang et al. “Trojan horse” nanoparticle-delivered cancer cell membrane vaccines to enhance cancer immunotherapy by overcoming immune-escape
KR101591927B1 (ko) 고분자 나노입자 기반의 암 백신 조성물
CN1549728A (zh) 在可生物降解的微球体中含有抗原、基因载体和佐剂的免疫组合物
Lacinski et al. Synthesis, characterization, and in vivo cytokinome profile of IL‐12‐loaded PLGA nanospheres
CN108379562B (zh) 一种聚合物纳米佐剂及其制备方法和用途
HK40083735A (en) Protein-loaded plga nanospheres
Markel et al. Nanocapsule delivery of IL-12
JP4688254B2 (ja) 腫瘍ワクチン
CN118717701A (zh) 细菌矿化金属纳米颗粒用于治疗肿瘤
EP2925297B1 (en) Composition comprising cytokine macro-aggregates
Xu et al. Enhancement of intranasal mucosal immunization of mucosal vaccines by ultrasonic treatment
CN118436806A (zh) 一种基于PLGA的OVA-aPD1纳米/微米球混合制剂及其制备方法和应用
Bhattacharjee et al. Immunomodulatory Role of Methotrexate and Paclitaxel and Their Nanoparticles in Cancer Therapeutics
CN118948769A (zh) 一种用于肿瘤免疫治疗的超声-自裂解il-12聚合物囊泡及制备方法
Meher et al. Macrophage Targeting: A Promising Strategy for Delivery of Chemotherapeutics in Leishmaniasis and Other Visceral Diseases
CN119185522A (zh) 一种载细菌全抗原的plga微球疫苗及其制备方法与应用